國家衛生研究院 NHRI:Item 3990099045/14504
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12500/13673 (91%)
造訪人次 : 2831404      線上人數 : 765
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/14504


    題名: Toward collaboration among cancer trials groups in Asia: TCOG perspective
    作者: Chen, LT
    貢獻者: National Institute of Cancer Research
    摘要: It has been well recognized that investigator-initiated academic clinical trials is an important component in developing practice-changing cancer treatment, for instances, FOLFIRINOX in metastatic and resectable pancreatic cancer and FLOT in locally advanced gastric cancer. Because of the difference in prevalent cancer types, pharmacogenomics, tumor biology and/or associated genetic alterations, and new drug approval/reimbursement, clinical practice pattern and subsequent patient outcomes between Eastern and Western populations, the role for such academic clinical intervention trials, including real-world data (RWD) collection registration trials, to investigate the safety and efficacy of repurposing or new agents for new indications evaluation is even more relevant in Asia. Facing the rapid advances in modern biotechnology and biomarker-enriched molecular targeted/immunotherapy, multi-national intergroup study is an attractive model to collect sufficient patients or data in a reasonable period of time for non-industry sponsored trials. Taiwan Cooperative Oncology Group (TCOG) is a government funding supported organization with extensive domestic, multicenter trial experience. However, international collaborative academic trials are much more challenging. From our previous experience, hurdles existed, such as, ethical and privacy protection issue of real world data sharing, funding and medication availability issues for intervention trials, translational tissue acquisition, storage and usage and NGS issue for biomarker-driven trials, etc. The real-world cases will be presented in the meeting!
    日期: 2022-07
    關聯: Annals of Oncology. 2022 Jul;33(Suppl. 6):S449.
    Link to: http://dx.doi.org/10.1016/j.annonc.2022.05.491
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000834940400107
    顯示於類別:[陳立宗] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000834940400107.pdf109KbAdobe PDF150檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋